Advances in the field have enabled the development of effective therapies, such as inhibitors that target oncogenic BRAF protein, the product of V600 mutations of BRAF. Patients with activating BRAF mutations constitute up to 50% of melanoma patients1, 2 and frequently respond to BRAF-inhibitor treatment3. Here, BRAF is linked to melanoma.